Ab­b­Vie gets its first ap­proval for a drug ex­ecs be­lieve could be worth up to $5B in an­nu­al sales

Ab­b­Vie has tacked down its first reg­u­la­to­ry ap­proval for risankizum­ab as it be­gins what it hopes is a glob­al roll­out for the pso­ri­a­sis drug in 2019 with a plan to quick­ly at­tain megablock­buster sta­tus.

Japan be­came the first coun­try to stamp an OK on the drug, which has been dubbed Skyrizi for the mar­ket­ing cam­paign. Eval­u­ate has tagged this IL-23 drug as the num­ber 3 block­buster on its list of heavy­weight drugs look­ing at a 2019 launch. They be­lieve this drug could earn more than $2 bil­lion in 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.